Cumulative incidences for any cancer at 75 years in path_MLH1 carriers with truncating or missense/aberrant splicing variants were 75.4% (95% CI (69.1–81.8)) versus 83.5% (95% CI (71.4–95.6)), respectively, and in path_MSH2 carriers 80.3% (95% CI (73.3–87.4)) versus 87.1% (95% CI (75.6–98.6)), respectively. The gene discussed is MSH2; the disease is cancer.